Pictet Asset Management Holding SA Buys 140,605 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)

Pictet Asset Management Holding SA increased its stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS) by 13.8% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 1,157,452 shares of the company’s stock after purchasing an additional 140,605 shares during the period. Pictet Asset Management Holding SA owned 1.25% of NewAmsterdam Pharma worth $29,747,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in NAMS. Geode Capital Management LLC lifted its holdings in shares of NewAmsterdam Pharma by 1.6% in the third quarter. Geode Capital Management LLC now owns 86,322 shares of the company’s stock worth $1,433,000 after buying an additional 1,399 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in NewAmsterdam Pharma in the 4th quarter worth approximately $80,000. KLP Kapitalforvaltning AS bought a new position in NewAmsterdam Pharma in the 4th quarter valued at $154,000. Quarry LP grew its position in shares of NewAmsterdam Pharma by 2,469.2% during the 3rd quarter. Quarry LP now owns 6,500 shares of the company’s stock valued at $108,000 after purchasing an additional 6,247 shares in the last quarter. Finally, Barclays PLC increased its holdings in shares of NewAmsterdam Pharma by 1,813.4% in the third quarter. Barclays PLC now owns 7,596 shares of the company’s stock worth $126,000 after purchasing an additional 7,199 shares during the period. Institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Stock Performance

NAMS stock opened at $21.76 on Monday. NewAmsterdam Pharma has a one year low of $15.19 and a one year high of $27.29. The company has a market capitalization of $2.39 billion, a PE ratio of -8.37 and a beta of -0.04. The company’s 50 day moving average price is $21.66 and its two-hundred day moving average price is $21.27.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The business had revenue of $12.77 million for the quarter, compared to analyst estimates of $3.30 million. On average, research analysts predict that NewAmsterdam Pharma will post -1.75 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on NAMS shares. UBS Group set a $41.00 target price on NewAmsterdam Pharma in a research report on Monday, March 3rd. HC Wainwright restated a “buy” rating and issued a $48.00 price objective on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Needham & Company LLC dropped their target price on shares of NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating for the company in a research report on Thursday, February 27th. Scotiabank increased their price target on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a report on Thursday, February 27th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $40.00 price objective on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, NewAmsterdam Pharma has a consensus rating of “Buy” and a consensus price target of $43.33.

Insider Buying and Selling

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 150,000 shares of the stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the completion of the sale, the chief accounting officer now owns 15,000 shares of the company’s stock, valued at $305,550. This represents a 90.91 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director James N. Topper acquired 1,135 shares of the firm’s stock in a transaction on Wednesday, March 26th. The stock was purchased at an average price of $22.49 per share, for a total transaction of $25,526.15. Following the transaction, the director now directly owns 3,013,569 shares of the company’s stock, valued at approximately $67,775,166.81. This trade represents a 0.04 % increase in their position. The disclosure for this purchase can be found here. 19.50% of the stock is owned by corporate insiders.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.